The Oxford AHSN has helped NHS partners across the region secure funding totalling more than £300,000 to develop services in line with national priorities.
The funds will speed up the integration of proven clinical innovations into everyday practice, bringing tangible patient benefits. They include:
- redeveloping asthma pathways, with a particular focus on treatments for severe asthma, working with Oxford University Hospitals and the Buckinghamshire, Oxfordshire and Berkshire West Integrated Care System
- delivering FeNO* testing to aid asthma diagnosis by installing monitors in four primary care network areas (Banbury, Berinsfield, Bracknell and Oxford)
- transforming the lipid management pathway to reduce cholesterol, working with the new Bedfordshire, Luton and Milton Keynes Clinical Commissioning Group
They were among 51 projects nationwide supported through the £2.8m Pathway Transformation Fund.
The Oxford AHSN is the national lead for Asthma Biologics which can transform the lives of people affected by severe asthma by reducing asthma attacks, asthma-related hospital admissions and the long-term side effects of other treatments such as oral steroids. Our Clinical Innovation Adoption and Strategic & Industry Partnerships teams are working closely with neighbouring Wessex AHSN on asthma pathways and diagnosis.
- In further successful joint funding bids, the Oxford AHSN’s Strategic and Industry Partnerships team and partners secured more than £5m through the first two rounds of the NHS Artificial Intelligence in Health and Care Award.
* FeNO = fractional exhaled nitric oxide (FeNO)